NCT03905148 : A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Bowel (colorectum),Female reproductive organs,Head and neck,Lung,Skin,Stomach and upper gastrointestinal tractColon,Colorectum,Endometrium,Head and neck,Lung,Melanoma (Ocular),Melanoma (Skin),Non-Small Cell Lung Cancer,Ovary,Pancreas,Rectum,Thyroid

Trial Overview Read MoreRead more

This Phase I/II trial is trying to determine the safety and recommended dose of two drugs (PD-0325901 and BGB-283) given in combination for the treatment of advanced solid cancers.
 

This trial is treating multiple types of cancer including non-small cell lung cancer, colorectal cancer, ovarian cancer, endometrial cancer, thyroid cancer, melanoma, pancreatic cancer, and other solid cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors

Commercial Sponsor

BeiGene Australia Pty Ltd

Summary

This trial consists of two parts. In part A, dose escalation and expansion, participants will receive increasing doses of PD-0325901 and BGB-283 in order to establish the maximum tolerated dose and/or recommended part B dose. In part B, participants will be stratified according to select tumour types and/or characteristics. This part of the trial will continue to evaluate the safety, tolerability and and Pharmacokinetics ot the combination of PD-0325901 and BGB-283.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next